Arthur O. Tzianabos Ph.D.
Net Worth
Last updated:
What is Arthur O. Tzianabos Ph.D. net worth?
The estimated net worth of Dr. Arthur O. Tzianabos Ph.D. is at least $7,172,927 as of 9 Jan 2023. He has earned $1,857,167 from insider trading and has received compensation worth at least $5,315,760 in Homology Medicines, Inc..
What is the salary of Arthur O. Tzianabos Ph.D.?
Dr. Arthur O. Tzianabos Ph.D. salary is $885,960 per year as Pres, Chief Executive Officer & Director in Homology Medicines, Inc..
How old is Arthur O. Tzianabos Ph.D.?
Dr. Arthur O. Tzianabos Ph.D. is 62 years old, born in 1963.
What stocks does Arthur O. Tzianabos Ph.D. currently own?
As insider, Dr. Arthur O. Tzianabos Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Homology Medicines, Inc. (FIXX) | Pres, Chief Executive Officer & Director | 108,395 | $0 | $0 |
What does Homology Medicines, Inc. do?
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Arthur O. Tzianabos Ph.D. insider trading
Homology Medicines, Inc.
Dr. Arthur O. Tzianabos Ph.D. has made 11 insider trades between 2019-2023, according to the Form 4 filled with the SEC. Most recently he sold 10,616 units of FIXX stock worth $14,767 on 9 Jan 2023.
The largest trade he's ever made was exercising 19,140 units of FIXX stock on 1 Jan 2023. As of 9 Jan 2023 he still owns at least 108,395 units of FIXX stock.
Homology Medicines key executives
Homology Medicines, Inc. executives and other stock owners filed with the SEC:
- Dr. Albert Seymour Ph.D. (57) Chief Scientific Officer
- Dr. Arthur O. Tzianabos Ph.D. (62) Pres, Chief Executive Officer & Director
- Mr. W. Bradford Smith CPA, M.B.A. (69) Chief Financial Officer & Treasurer